Physician profile
Roy Beaty
NPI 1427037795
$6,111.65
in general payments reported to CMS, 2019-2025
29 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what 93% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $253 · 2021: $403 · 2022: $437 · 2023: $948 · 2024: $2,188 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $1,998 · Food and Beverage: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $1,998.15 |
| Food and Beverage | $137.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,909.39 | 2023-2025 | Da Vinci Surgical System |
| Coloplast Corp | $711.86 | 2022-2023 | Restorelle, Altis |
| Abbvie INC. | $618.29 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Therapeuticsmd, INC. | $122.91 | 2019-2021 | |
| Astellas Pharma US INC | $101.96 | 2020-2022 | |
| Medtronic, INC. | $83.85 | 2022-2023 | Truclear |
| Pfizer INC. | $82.20 | 2021-2022 | |
| Aspira Women'S Health INC | $46.29 | 2020 | |
| Myovant Sciences INC. | $36.42 | 2021-2022 | |
| Evofem Biosciences, INC. | $33.99 | 2021 | |
| Organon LLC | $33.35 | 2021-2022 | |
| Becton, Dickinson and Company | $30.76 | 2022 | |
| Davol INC. | $26.83 | 2021 | |
| Merck Sharp & Dohme LLC | $23.20 | 2020 | |
| Amag Pharmaceuticals, INC. | $22.65 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $21.50 | 2021 | |
| Mallinckrodt Enterprises LLC | $21.43 | 2019 | |
| Radius Health, INC. | $19.65 | 2020 | |
| Smith+Nephew, INC. | $19.43 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.73 | 2021 | |
| Osiris Therapeutics INC. | $15.72 | 2019 | |
| Minerva Surgical, INC | $15.55 | 2021 | |
| Novo Nordisk INC | $15.01 | 2020 | |
| Amgen INC. | $14.73 | 2020 | |
| Roche Diagnostics Corporation | $14.71 | 2019 | |
| Coopersurgical, INC. | $14.12 | 2019 | |
| Mission Pharmacal Company | $13.91 | 2019 | |
| Heron Therapeutics, INC. | $12.16 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Beaty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.